Drugs / Nuronox
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01664013 | Oct 2012 → Oct 2013 | cervical dystonia | Roongroj Bhidayasiri | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nuronox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01664013 ↗ |
| Known as | Neuronox | “Neuronox® is a botulinum toxin type A (BoNT/A) product developed by Medytox Inc. (Medytox) of Korea.” NCT01664013 ↗ |
| Modality | Protein / enzyme biologic | “botulinum toxin type A (BoNT/A) product” NCT01664013 ↗ |